Umifenovir, 100 mg capsules 10 pcs

.

Indications

Prevention and treatment of influenza A and B, other acute respiratory infections in adults and children from 3 years (for dosage form of 50 mg capsules), from 6 years (for dosage form of 100 mg capsules).

The complex therapy of recurrent herpetic infection.

Prevention of postoperative infectious complications.

Active ingredient

Umifenovir

Composition

Composition per 1 capsule 100 mg:

Active ingredient: umiphenovir hydrochloride monohydrate – 103.50 mg converted into umiphenovir hydrochloride – 100.00 mg.

Excipients: microcrystalline cellulose – 63.70 mg; potato starch – 33.00 mg; povidone-K25 – 11.00 mg; croscarmellose sodium – 4.40 mg; colloidal silica – 2.20 mg; magnesium stearate – 2.20 mg.

Capsule body composition: titanium dioxide – 2.0000%; gelatin – up to 100%.

Capsule cap composition: quinoline yellow dye – 0.7500%; sunset yellow dye – 0.0059%; titanium dioxide – 2.0000%; gelatin – up to 100%.

How to take, the dosage

Ingestively, before meals.

Dose per day: For children 3 to 6 years old – 50 mg, 6 to 12 years old – 100 mg (1 capsule of 100 mg or 2 capsules of 50 mg), over 12 years old and adults – 200 mg (2 capsules of 100 mg or 4 capsules of 50 mg).

For non-specific prevention and treatment of influenza and other acute respiratory infections in children and adults:

Nonspecific prophylaxis:

During epidemics of influenza and other acute respiratory infections: children 3 to 6 years – 50 mg, 6 to 12 years – 100 mg, over 12 years and adults – 200 mg twice a week for 3 weeks.

In direct contact with patients with influenza and other acute respiratory infections: children 3 to 6 years – 50 mg, 6 to 12 years – 100 mg, older than 12 years and adults – 200 mg once a day for 10-14 days.

The treatment of influenza and other acute respiratory infections: children 3 to 6 years – 50 mg, 6 to 12 years – 100 mg, older than 12 years and adults – 200 mg 4 times a day (every 6 hours) for 5 days.

In complex therapy of recurrent herpes infection: to children from 3 to 6 years old – 50 mg, from 6 to 12 years old – 100 mg, over 12 years old and adults – 200 mg 4 times daily (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.

Prevention of postoperative infectious complications: to children from 3 to 6 years – 50 mg, 6 to 12 years – 100 mg, over 12 years and adults – 200 mg 2 days before surgery, then on the 2nd and 5th day after surgery.

The drug should be taken from the time of the first symptoms of influenza and other acute respiratory infections, preferably within 3 days from the beginning of the disease. If after using the drug for three days during the treatment of influenza and other acute respiratory viral infections the severity of symptoms persists, including high temperature (over 38 ° C and more), it is necessary to see a doctor to assess the feasibility of taking the drug.

The drug should only be used according to the indication, route of administration, and dosage listed in the directions.

Interaction

When administered with other medicinal products no adverse effects have been noted.

Special clinical studies to study interactions of umifenovir with other medicinal products have not been conducted.

There have been no reports of adverse interactions with antipyretics, mucolytic and local vasoconstrictors in clinical trials.

Special Instructions

.

Synopsis

Solid gelatin capsules № 2. The body is white, the cap is yellow, opaque.

The capsule contents: a mixture of powder and granules from white to white with a greenish-yellow or beige tint. The contents of the capsule may be compacted into lumps, which disintegrate on pressure.

Contraindications

Hypersensitivity to umifenovir or any drug component, children under 3 years of age (for dosage form 50 mg), under 6 years of age (for dosage form 100 mg), first trimester of pregnancy, breastfeeding.

With caution:

.

Side effects

Umifenovir is a low-toxicity drug and is usually well tolerated. Side effects are rare, usually mild to moderate and transient.

The incidence of adverse drug reactions has been defined according to the WHO classification: very rare (with an incidence of more than 1/10), frequent (with an incidence of at least 1/100 but less than 1/10), infrequent (with an incidence of at least 1/1000 but less than 1/100), rare (with an incidence of at least 1/10000 but less than 1/1000), very rare (with an incidence of less than 1/10), unknown (cannot be known from available data).

Immune system disorders: rare – allergic reactions.

If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.

Pregnancy use

Harmful effects on pregnancy, embryo and fetal development, labor and postnatal development have not been found in animal studies.

The use of the drug is contraindicated in the first trimester of pregnancy.

In the second and third trimesters of pregnancy, the drug can be used only for the treatment and prevention of influenza and when the expected benefits to the mother exceed the potential risk to the fetus. The benefit/risk ratio is determined by the treating physician.

It is not known whether umifenovir penetrates into breast milk in women during lactation. Breastfeeding should be discontinued if the drug has to be used.

Similarities

Arbidol, Arbidol Maximum, Arpeflu, Afludol